Fulcrum Therapeutics, Inc.
FULC
$3.74
$0.030.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 0.00 |
| Cost of Revenue | 44.50M | 44.35M | 43.67M | 39.97M | 40.31M |
| Gross Profit | -44.50M | -44.35M | -43.67M | -39.97M | -40.31M |
| SG&A Expenses | 30.40M | 29.77M | 28.67M | 29.11M | 29.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.64M | 86.55M | 84.77M | 81.51M | 82.71M |
| Operating Income | -86.64M | -86.55M | -84.77M | -81.51M | -82.71M |
| Income Before Tax | -85.00M | -76.12M | -74.88M | -71.11M | -73.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -85.00 | -76.12 | -74.88 | -71.11 | -73.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -85.00M | -76.12M | -74.88M | -71.11M | -73.22M |
| EBIT | -86.64M | -86.55M | -84.77M | -81.51M | -82.71M |
| EBITDA | -85.40M | -85.18M | -83.38M | -80.09M | -81.28M |
| EPS Basic | -1.21 | -1.15 | -1.18 | -1.18 | -1.21 |
| Normalized Basic EPS | -0.68 | -0.72 | -0.74 | -0.74 | -0.74 |
| EPS Diluted | -1.22 | -1.15 | -1.18 | -1.18 | -1.22 |
| Normalized Diluted EPS | -0.68 | -0.72 | -0.74 | -0.74 | -0.74 |
| Average Basic Shares Outstanding | 280.86M | 267.14M | 253.40M | 241.57M | 241.39M |
| Average Diluted Shares Outstanding | 280.86M | 267.14M | 253.40M | 241.57M | 241.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |